Alnylam Pharmaceuticals
ALNY
#590
Rank
โ‚ฌ30.34 B
Marketcap
236,35ย โ‚ฌ
Share price
2.22%
Change (1 day)
24.41%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total debt

Total debt on the balance sheet as of June 2024 : โ‚ฌ1.17 B

According to Alnylam Pharmaceuticals 's latest financial reports the company's total debt is โ‚ฌ1.17 B. A companyโ€™s total debt is the sum of all current and non-current debts.

Alnylam Pharmaceuticals - Total debt on balance sheet (from 2003 to 2024)

Total debt by year

Year Total debt Change
2023-12-31โ‚ฌ1.18 B-4.06%
2022-12-31โ‚ฌ1.23 B40.36%
2021-12-31โ‚ฌ0.87 B105.66%
2020-12-31โ‚ฌ0.42 B57.57%
2019-12-31โ‚ฌ0.27 B933.23%
2018-12-31โ‚ฌ26.18 M4.74%
2017-12-31โ‚ฌ25 M-82.47%
2016-12-31โ‚ฌ0.14 B
2007-12-31โ‚ฌ4.58 M-33.8%
2006-12-31โ‚ฌ6.92 M10.91%
2005-12-31โ‚ฌ6.24 M31.07%
2004-12-31โ‚ฌ4.76 M220.04%
2003-12-31โ‚ฌ1.48 M

Total debt for similar companies or competitors

Company Total debt differencediff. Country
โ‚ฌ0.10 B-90.94%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ2.43 B 107.38%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ1.23 B 5.08%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ0.24 B-79.33%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ1.27 M-99.89%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ26.15 B 2,123.44%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
โ‚ฌ22.97 B 1,852.96%๐Ÿ‡ซ๐Ÿ‡ท France
โ‚ฌ17.07 B 1,351.41%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel